Wordt geladen...
Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this setting, and to-date several other agent...
Bewaard in:
| Hoofdauteurs: | , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Research Foundation
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3364443/ https://ncbi.nlm.nih.gov/pubmed/22666217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2012.00073 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|